Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 5/2010

01-05-2010 | Brief Report

Prevalence of antibiotics resistance and OXA carbapenemases genes in multidrug-resistant Acinetobacter baumannii isolates in central Taiwan

Authors: S.-C. Yang, W.-J. Chang, Y.-H. Chang, Y.-S. Tsai, T.-P. Yang, C.-W. Juan, M.-Y. Shiau

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 5/2010

Login to get access

Abstract

This study analyzed the prevalence of antibiotics resistance and the distribution of genes responsible for carbapenems resistance in Acinetobacter baumannii isolates. Clinical A. baumannii isolates were cultured, identified, and collected during the period from May 2007 to February 2009. Antibiotics resistance rates of the clinical isolates were analyzed by antimicrobial susceptibility testing. The distribution of carbapenemase alleles were investigated in the multidrug-resistant (MDR) A. baumannii isolates by multiplex polymerase chain reaction (PCR) techniques. A total of 1,265 independent A. baumannii isolates were identified. Approximately 70% of the clinical isolates were resistant to ampicillin/sulbactam, followed by imipenem, meropenem, cefepime, piperacillin/tazobactam, ceftazidime, and cefoperazone. Overall, 15.18% (192/1,265) of the isolates were characterized as MDR strains. All of the MDR A. baumannii isolates carried the bla OXA51-like allele. The detection rate of the bla OXA23-like and bla OXA24-like alleles was 96.35% (185/192) and 0.52% (1/192), respectively. Most of the isolates (185/192, 96.35%) carried genes which encode more than one carbapenemase. This report demonstrated that approximately 15% of A. baumannii clinical isolates in central Taiwan are MDR strains, with most of them harboring multiple carbapenemases. This study provides updated data regarding the prevalence of β-lactam resistance and genotyping information of carbapenems resistance of A. baumannii in central Taiwan.
Literature
1.
go back to reference Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y (2005) Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 11:22–29PubMed Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y (2005) Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis 11:22–29PubMed
2.
go back to reference Jain R, Danziger LH (2004) Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 38:1449–1459CrossRefPubMed Jain R, Danziger LH (2004) Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother 38:1449–1459CrossRefPubMed
3.
go back to reference García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jiménez-Jiménez FJ, Pérez-Paredes C, Barrero-Almodóvar AE, Gili-Miner M (2001) Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 33:939–946CrossRefPubMed García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jiménez-Jiménez FJ, Pérez-Paredes C, Barrero-Almodóvar AE, Gili-Miner M (2001) Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 33:939–946CrossRefPubMed
4.
go back to reference Fournier PE, Richet H (2006) The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42:692–699CrossRefPubMed Fournier PE, Richet H (2006) The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42:692–699CrossRefPubMed
5.
go back to reference Bergogne-Bérézin E, Towner KJ (1996) Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9:148–165PubMed Bergogne-Bérézin E, Towner KJ (1996) Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 9:148–165PubMed
6.
go back to reference Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, Mosinka-Snipas K, Rahal JJ (1994) Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344:1329–1332CrossRefPubMed Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, Mosinka-Snipas K, Rahal JJ (1994) Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344:1329–1332CrossRefPubMed
7.
go back to reference Afzal-Shah M, Livermore DM (1998) Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 41:576–577CrossRefPubMed Afzal-Shah M, Livermore DM (1998) Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 41:576–577CrossRefPubMed
8.
go back to reference Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA (2007) Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51:3471–3484CrossRefPubMed Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA (2007) Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51:3471–3484CrossRefPubMed
9.
go back to reference Ayats J, Corbella X, Ardanuy C, Domínguez MA, Ricart A, Ariza J, Martin R, Liñares J (1997) Epidemiological significance of cutaneous, pharyngeal, and digestive tract colonization by multiresistant Acinetobacter baumannii in ICU patients. J Hosp Infect 37:287–295CrossRefPubMed Ayats J, Corbella X, Ardanuy C, Domínguez MA, Ricart A, Ariza J, Martin R, Liñares J (1997) Epidemiological significance of cutaneous, pharyngeal, and digestive tract colonization by multiresistant Acinetobacter baumannii in ICU patients. J Hosp Infect 37:287–295CrossRefPubMed
10.
go back to reference Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (1999) Manual of clinical microbiology, 7th edn. American Society for Microbiology, Washington, DC Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (1999) Manual of clinical microbiology, 7th edn. American Society for Microbiology, Washington, DC
11.
go back to reference Clinical and Laboratory Standards Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing; Nineteenth Informational Supplement 28:M100-S19 Clinical and Laboratory Standards Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing; Nineteenth Informational Supplement 28:M100-S19
12.
go back to reference Liu SY, Lin JY, Chu C, Su LH, Lin TY, Chiu CH (2006) Integron-associated imipenem resistance in Acinetobacter baumannii isolated from a regional hospital in Taiwan. Int J Antimicrob Agents 27:81–84CrossRefPubMed Liu SY, Lin JY, Chu C, Su LH, Lin TY, Chiu CH (2006) Integron-associated imipenem resistance in Acinetobacter baumannii isolated from a regional hospital in Taiwan. Int J Antimicrob Agents 27:81–84CrossRefPubMed
13.
go back to reference Lauderdale TL, McDonald LC, Shiau YR, Chen PC, Wang HY, Lai JF, Ho M; TSAR Participating Hospitals (2004) The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000. Diagn Microbiol Infect Dis 48:211–219CrossRefPubMed Lauderdale TL, McDonald LC, Shiau YR, Chen PC, Wang HY, Lai JF, Ho M; TSAR Participating Hospitals (2004) The status of antimicrobial resistance in Taiwan among gram-negative pathogens: the Taiwan surveillance of antimicrobial resistance (TSAR) program, 2000. Diagn Microbiol Infect Dis 48:211–219CrossRefPubMed
Metadata
Title
Prevalence of antibiotics resistance and OXA carbapenemases genes in multidrug-resistant Acinetobacter baumannii isolates in central Taiwan
Authors
S.-C. Yang
W.-J. Chang
Y.-H. Chang
Y.-S. Tsai
T.-P. Yang
C.-W. Juan
M.-Y. Shiau
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 5/2010
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-010-0878-2

Other articles of this Issue 5/2010

European Journal of Clinical Microbiology & Infectious Diseases 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.